The Pros and Cons of Buying Social Capital Hedosophia VI Stock for $15 Per Share

The Pros and Cons of Buying Social Capital Hedosophia VI Stock for $15 Per Share

Trade CLOV on Coinbase

Social Capital Hedosophia VI (NYSE:IPOF) stock is the latest SPAC (special purpose acquisition company) from investor Chamath Palihapitiya. Based on his strong track record, which includes past winners like Virgin Galactic (NYSE:SPCE), IPOF stock has been bid up to around $15 per share, representing a 50% premium to its offering price.

IPOF stock
IPOF stock

The SPAC is yet to announce a merger deal. Bill Ackman’s SPAC, Pershing Square Tontine (NYSE:PSTH), is in a similar situation. Just like Social Capital, PSTH trades at a rich premium to its offering price, mainly based on the reputation of its sponsor.

I don’t understand why anyone would pay a 50% premium for what amounts to a pile of cash. I prefer “buy a dollar for 50 cents” kinds of situations. But, given Palihapitiya’s Silicon Valley ties and his clout among retail investors, paying a premium for this SPAC may make more sense than paying one for Ackman’s SPAC.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

Yet IPOF stock is more a name to gamble on, rather than shares to invest in. In other words, those who buy the shares are betting that the SPAC mania can continue, rather than that this particular SPAC will announce a game-changing deal.

Admittedly, the risk of buying IPOF stock isn’t as massive as it looks at first glance. If Social Capital doesn’t merge with a target company, its shares will fall back to $10. But, if it announces such a deal amidst a great deal of SPAC hype, the stock could hit $30 per share.

Why IPOF Stock Is Worth Buying for $15

Despite the stock’s premium, its potential reward may outweigh its risk, based on the performance of Chamath Palihapitiya’s prior SPACs.

As InvestorPlace columnist Vince Martin broke it down in his Feb. 12 article, most of the Social Capital SPACs have performed well. The only one that had some trouble was IPOD stock, which became Clover Health (NASDAQ:CLOV). Yet, even though that company is facing a scandal, its stock today is trading for $10.67 per share, which is still above the SPAC’s $10 per share offering price.

Assuming today’s unique market environment continues, even if Social Capital Hedosophia VI chooses the wrong merger partner, the risk facing IPOF stock may be lower than it appears at first glance. However, the keyword is “today’s unique market environment.” The bears have lost big trying to find a top in this manic stock market.

Yet we could be approaching the point where the music stops. Again, in such a scenario the declines of IPOF stock could be limited, since the SPAC so far hasn’t announced a deal. But after the SPAC has merged with an operating business, its shares could fall meaningfully once the SPAC euphoria ends.